Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

In the 2010 Journal Citation Reports, The Lancet s impact factor was ranked second among general medical journals, at 33.63, after The New England Journal of Medicine (53.48). The Lancet also has ...

The full manuscript was subsequently published in The New England Journal of Medicine on January 22, 2025. The published results closely match the presentation. Find our full coverage below.

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Operator: Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for ...

Additionally, in October, we announced the publication of the Accuray sponsored PACE-B trial in the New England Journal of Medicine ... and other service cost impact of approximately 2.7 points.